Overview of the Research
We are involved in all Gastroenterology studies with a current interest in IBD studies, both Ulcerative colitis and Crohn’s disease.
The GI Research team was first established in 2002 with one research nurse and one consultant. Our first study looked at the effectiveness of anti-reflux oesophageal stents and our portfolio of studies has rapidly grown over the past decade.
Mission Statement: Translating today’s science into tomorrow’s treatments
Currently we are inviting all the IBD patients in Bradford to participate in the IBD bioresource which is part of the NIHR Bioresource. The IBD Bioresource is a national platform designed to expedite research into Crohn’s disease and ulcerative colitis and help develop new and better therapies.
The GI Research team consists of a Consultant Gastroenterologist and 1.6 WTE research nurses. We have access to the Trust’s Clinical Research Facility and receive good feedback on our first class facilities and service to our clients.
We regularly obtain feedback from our patients and have recently set up a generic e-mail account to which we can arrange appointments or just answer general enquiries.
Interested in getting involved with GI research?
Contact Sophie or Wendy in the first instance:
P: 01274 276375
The Research Team
Dr Cathryn Preston
About IBD BioResource
The IBD Bioresource is a national platform designed to expedite research into Crohn’s disease and ulcerative colitis and help develop new and better therapies.
To recruit 25,000 patients with Crohn’s or colitis from all over the UK, including 1000 newly diagnosed
Genetic analysis will identify markers of disease risk, severity and treatment response
Participants will be directly notified of future IBD research projects they might be willing to help with and be recalled for
Scientists and Clinical Investigators will have rapid access to large groups of IBD patients for research
IBD Cancer and Serious Infection in Europe (I-CARE)
The primary objective of I-CARE is to assess prospectively the presence and the extent of safety concerns (cancers, especially, lymphoma, and serious infections risks) for anti-TNF alone or in combination with thiopurines among IBD patients.
We will stratify the risk of cancers and serious infections according to IBD phenotype and disease activity (clinical, radiologic and endoscopic).
Predicting Serious Drug Side Effects in Gastroenterology – PRED4
This group of studies is looking at the following drug side effects in IBD.
Thiopurine included myelosuppression
Thiopurine induced pancreatitis
Anti-TNF induced demyelination
PPI induced interstitial nephritis
Thiopurine Induced Liver Injury
Sulfasalazine Induced Neutropaenia
Thiopurine Hypersensitivity Reaction
The Bradford GI research team were the top recruiters in the CReST trial which was a multi-centred colorectal stenting trial.
We are currently 5th place in Yorkshire for I-CARE
Efficacy and safety of Golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom
The Gastro team recently opened their first commercial study, Go-colitis. This study looked at Golimumab Utilization and Impact on Ulcerative Colitis. We managed to enrol 4 patients into this phase IV trial within a relatively short window of recruitment. The patients self-administer the Golimumab at home every 4 weeks and early results show good responses to the drug.
Leading on from this first taste of commercial research, the team continue to be approached for more involvement in further early stage drug development for patients with Ulcerative colitis. We hope to be involved in some phase II work in the not so distant future